• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

等位基因特异性基因编辑可预防显性进行性听力损失模型中的耳聋。

Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss.

机构信息

Department of Neurobiology, Harvard Medical School, Boston, MA, USA.

Department of Neurology, The Massachusetts General Hospital, Boston, MA, USA.

出版信息

Nat Med. 2019 Jul;25(7):1123-1130. doi: 10.1038/s41591-019-0500-9. Epub 2019 Jul 3.

DOI:10.1038/s41591-019-0500-9
PMID:31270503
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6802276/
Abstract

Since most dominant human mutations are single nucleotide substitutions, we explored gene editing strategies to disrupt dominant mutations efficiently and selectively without affecting wild-type alleles. However, single nucleotide discrimination can be difficult to achieve because commonly used endonucleases, such as Streptococcus pyogenes Cas9 (SpCas9), can tolerate up to seven mismatches between guide RNA (gRNA) and target DNA. Furthermore, the protospacer-adjacent motif (PAM) in some Cas9 enzymes can tolerate mismatches with the target DNA. To circumvent these limitations, we screened 14 Cas9/gRNA combinations for specific and efficient disruption of a nucleotide substitution that causes the dominant progressive hearing loss, DFNA36. As a model for DFNA36, we used Beethoven mice, which harbor a point mutation in Tmc1, a gene required for hearing that encodes a pore-forming subunit of mechanosensory transduction channels in inner-ear hair cells. We identified a PAM variant of Staphylococcus aureus Cas9 (SaCas9-KKH) that selectively and efficiently disrupted the mutant allele, but not the wild-type Tmc1/TMC1 allele, in Beethoven mice and in a DFNA36 human cell line. Adeno-associated virus (AAV)-mediated SaCas9-KKH delivery prevented deafness in Beethoven mice up to one year post injection. Analysis of current ClinVar entries revealed that ~21% of dominant human mutations could be targeted using a similar approach.

摘要

由于大多数显性人类突变是单核苷酸替换,我们探索了基因编辑策略,以有效地和选择性地破坏显性突变,而不影响野生型等位基因。然而,单核苷酸的区分可能很难实现,因为常用的内切酶,如酿脓链球菌 Cas9(SpCas9),可以在向导 RNA(gRNA)和靶 DNA 之间容忍多达七个错配。此外,一些 Cas9 酶中的原间隔基序(PAM)可以容忍与靶 DNA 的错配。为了规避这些限制,我们筛选了 14 种 Cas9/gRNA 组合,以特异性和有效地破坏导致显性进行性听力损失 DFNA36 的核苷酸替换。作为 DFNA36 的模型,我们使用了贝多芬小鼠,其携带了 Tmc1 中的一个点突变,该基因是听力所必需的,编码内耳毛细胞机械感觉转导通道的孔形成亚基。我们鉴定了一种金黄色葡萄球菌 Cas9(SaCas9-KKH)的 PAM 变体,它可以选择性和有效地破坏突变等位基因,但不破坏贝多芬小鼠和 DFNA36 人细胞系中的野生型 Tmc1/TMC1 等位基因。腺相关病毒(AAV)介导的 SaCas9-KKH 递送至贝多芬小鼠体内可预防耳聋,最长可达注射后一年。对当前 ClinVar 条目的分析表明,约 21%的显性人类突变可以使用类似的方法靶向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/6d9920d58903/nihms-1530254-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/87be95af3ef8/nihms-1530254-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/5cb2a8db601e/nihms-1530254-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/21a5b4373e2e/nihms-1530254-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/e195d7d91ac0/nihms-1530254-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/6a3ee77cc77a/nihms-1530254-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/377a87cfbd5b/nihms-1530254-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/ee55a8aabc44/nihms-1530254-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/70af6e14f019/nihms-1530254-f0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/0415dfe6511d/nihms-1530254-f0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/7eeade85e49a/nihms-1530254-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/59aeccc69dc3/nihms-1530254-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/8ab4fff24b20/nihms-1530254-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/6d9920d58903/nihms-1530254-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/87be95af3ef8/nihms-1530254-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/5cb2a8db601e/nihms-1530254-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/21a5b4373e2e/nihms-1530254-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/e195d7d91ac0/nihms-1530254-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/6a3ee77cc77a/nihms-1530254-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/377a87cfbd5b/nihms-1530254-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/ee55a8aabc44/nihms-1530254-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/70af6e14f019/nihms-1530254-f0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/0415dfe6511d/nihms-1530254-f0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/7eeade85e49a/nihms-1530254-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/59aeccc69dc3/nihms-1530254-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/8ab4fff24b20/nihms-1530254-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f023/6802276/6d9920d58903/nihms-1530254-f0004.jpg

相似文献

1
Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss.等位基因特异性基因编辑可预防显性进行性听力损失模型中的耳聋。
Nat Med. 2019 Jul;25(7):1123-1130. doi: 10.1038/s41591-019-0500-9. Epub 2019 Jul 3.
2
Single and Dual Vector Gene Therapy with AAV9-PHP.B Rescues Hearing in Tmc1 Mutant Mice.腺相关病毒 9-PHP.B 的单向量和双向量基因治疗可挽救 Tmc1 突变小鼠的听力。
Mol Ther. 2021 Mar 3;29(3):973-988. doi: 10.1016/j.ymthe.2020.11.016. Epub 2020 Nov 17.
3
Prevention of acquired sensorineural hearing loss in mice by in vivo Htra2 gene editing.通过体内 Htra2 基因编辑预防小鼠获得性感觉神经性听力损失。
Genome Biol. 2021 Mar 22;22(1):86. doi: 10.1186/s13059-021-02311-4.
4
Mutations of TMC1 cause deafness by disrupting mechanoelectrical transduction.TMC1基因的突变通过破坏机械电转导导致耳聋。
Auris Nasus Larynx. 2014 Oct;41(5):399-408. doi: 10.1016/j.anl.2014.04.001. Epub 2014 Jun 2.
5
Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents.体内递送基因编辑试剂治疗常染色体显性遗传性听力损失。
Nature. 2018 Jan 11;553(7687):217-221. doi: 10.1038/nature25164. Epub 2017 Dec 20.
6
A novel DFNA36 mutation in TMC1 orthologous to the Beethoven (Bth) mouse associated with autosomal dominant hearing loss in a Chinese family.在中国一个家族中,与常染色体显性听力损失相关的、与贝多芬(Bth)小鼠同源的TMC1基因中的一种新型DFNA36突变。
PLoS One. 2014 May 14;9(5):e97064. doi: 10.1371/journal.pone.0097064. eCollection 2014.
7
Tmc gene therapy restores auditory function in deaf mice.Tmc基因疗法可恢复耳聋小鼠的听觉功能。
Sci Transl Med. 2015 Jul 8;7(295):295ra108. doi: 10.1126/scitranslmed.aab1996.
8
Preventing autosomal-dominant hearing loss in Bth mice with CRISPR/CasRx-based RNA editing.使用基于 CRISPR/CasRx 的 RNA 编辑预防 Bth 小鼠的常染色体显性遗传性听力损失。
Signal Transduct Target Ther. 2022 Mar 14;7(1):79. doi: 10.1038/s41392-022-00893-4.
9
Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microRNA mutation.靶向基因组编辑恢复了由人类 microRNA 突变引起的进行性听力损失的成年小鼠的听觉功能。
Sci Transl Med. 2024 Jul 10;16(755):eadn0689. doi: 10.1126/scitranslmed.adn0689.
10
Gene editing in a Myo6 semi-dominant mouse model rescues auditory function.Myo6 半显性基因编辑小鼠模型挽救听觉功能。
Mol Ther. 2022 Jan 5;30(1):105-118. doi: 10.1016/j.ymthe.2021.06.015. Epub 2021 Jun 24.

引用本文的文献

1
Hearing loss: a global view for gene therapy approaches and challenges.听力损失:基因治疗方法与挑战的全球视角
Eur J Pediatr. 2025 Aug 27;184(9):578. doi: 10.1007/s00431-025-06426-9.
2
Exploring AAV-Mediated Gene Therapy for Inner Ear Diseases: from Preclinical Success to Clinical Potential.探索腺相关病毒介导的内耳疾病基因治疗:从临床前成功到临床潜力
Adv Sci (Weinh). 2025 Sep;12(33):e08397. doi: 10.1002/advs.202408397. Epub 2025 Jun 20.
3
M6Allele: a toolkit for detection of allele-specific RNA N6-methyladenosine modifications.
M6等位基因:一种用于检测等位基因特异性RNA N6-甲基腺嘌呤修饰的工具包。
Gigascience. 2025 Jan 6;14. doi: 10.1093/gigascience/giaf040.
4
Advancing precision ear medicine: leveraging animal models for disease insights and therapeutic innovations.推进精准耳医学:利用动物模型获取疾病见解和实现治疗创新。
Mamm Genome. 2025 Apr 22. doi: 10.1007/s00335-025-10126-y.
5
Current AAV-mediated gene therapy in sensorineural hearing loss.当前腺相关病毒介导的感音神经性听力损失基因治疗
Fundam Res. 2022 Sep 7;5(1):192-202. doi: 10.1016/j.fmre.2022.08.015. eCollection 2025 Jan.
6
Gene Therapy: An Historical Overview for Familial Hearing Loss.基因治疗:家族性听力损失的历史概述
Int J Mol Sci. 2025 Feb 10;26(4):1469. doi: 10.3390/ijms26041469.
7
Trichostatin A suppresses hearing loss by reducing oxidative stress and inflammation in an Alport syndrome model.曲古抑菌素A通过减轻阿尔波特综合征模型中的氧化应激和炎症来抑制听力损失。
PLoS One. 2025 Feb 5;20(2):e0316033. doi: 10.1371/journal.pone.0316033. eCollection 2025.
8
Haplotype editing with CRISPR/Cas9 as a therapeutic approach for dominant-negative missense mutations in .使用CRISPR/Cas9进行单倍型编辑作为治疗[疾病名称]中显性负性错义突变的一种治疗方法。 (注:原文中“in.”后面缺少具体疾病名称等相关内容,译文根据完整表达需求补充了[疾病名称])
bioRxiv. 2024 Dec 22:2024.12.20.629813. doi: 10.1101/2024.12.20.629813.
9
Defects in hair cells disrupt the development of auditory peripheral circuitry.毛细胞的缺陷会扰乱听觉外周神经回路的发育。
Nat Commun. 2024 Dec 30;15(1):10899. doi: 10.1038/s41467-024-55275-x.
10
Inner Ear Gene Therapy: An Overview from Bench to Bedside.内耳基因治疗:从实验台到病床边的概述
Mol Diagn Ther. 2025 Mar;29(2):161-181. doi: 10.1007/s40291-024-00759-1. Epub 2024 Dec 3.